Nachrichten zur ASTELLAS PHARMA INC. Aktie

Astellas fezolinetant to treat menopause symptoms gets FDA review

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Verizon Business selected to power Astellas infrastructure

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma GAAP EPS of ¥25.12, revenue of ¥381.79B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer

KENILWORTH (NJ) (dpa-AFX) - Japans Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) announced Tuesday positive topline results from…

Astellas/Seagen, Merck drug combo shows promise in bladder cancer subtype in trial

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash., July 26, 2022 /PRNewswire/ -- Astellas…

Astellas Unveils Plans to Open New Biotech Campus in South San Francisco

New 154,000-square-foot facility will provide a West Coast center with a focus on research, innovation, and commercial collaboration across corporate…

Mogrify, Astellas Pharma partner for sensorineural hearing loss treatment

Mogrify has developed a suite of platform technologies that use a systematic big-data approach for direct cellular reprogramming and to…

Astellas, Mogrify team up to discover regenerative medicines for hearing loss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mogrify, Astellas Pharma Announce Research Agreement

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Mogrify Limited and Astellas Pharma Inc. (ALPMY, ALPMY) have executed a collaborative research agreement on in vivo…

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

CAMBRIDGE, United Kingdom and TOKYO, July 5, 2022 /PRNewswire/ -- Mogrify Limited (CEO: Darrin M. Disley, Ph.D., "Mogrify®"), a biopharmaceutical…

Generian, Astellas to develop molecules for undruggable therapeutic targets

As part of the collaboration, both the companies will conduct research and preclinical development activities together for identifying new monovalent…

Astellas subsidiary Mitobridge in license agreement with Generian for undruggable targets

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

PITTSBURGH and CAMBRIDGE, Mass. , June 29, 2022 /PRNewswire/ -- Generian Pharmaceuticals, Inc. ("Generian") and Mitobridge, Inc. (a wholly owned…

Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration

Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients…

Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma

Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma...…

Sutro Biopharma gains nearly double after announcing worldwide strategic collaboration with Astellas Pharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas, Sutro Collaborate To Advance Novel Immunostimulatory Antibody-Drug Conjugates

BEIJING (dpa-AFX) - Astellas Pharma Inc. and Sutro Biopharma Inc. (STRO) announced a worldwide, strategic collaboration and licensing agreement focused…

Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas

Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas...…

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for…

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for…

Astellas gene replacement therapy trial put on hold by FDA after nerve issue in patient

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease

TOKYO, June 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that…

Astellas Pharma Submits Fezolinetant NDA To FDA

TOKYO (dpa-AFX) - Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food…

Astellas Submits Fezolinetant New Drug Application to U.S. FDA

Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas…

GlobalStem Cell Therapy Markets Research Report 2022-2031 Featuring Major Players - Anterogen; JCR Pharmaceuticals; Medipost; Osiris Therapeutics; Pharmicell; Astellas Pharma; Cellectis; Celyad

DUBLIN, June 21, 2022 /PRNewswire/ -- The "Stem Cell Therapy Global Market Report 2022: By Type, By Cell, By Application,…

Astellas unit to pay $20.5M upfront to GO Therapeutics in collaboration to discover cancer therapies

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Interstitial Cystitis Drugs Market - 36% of Growth to Originate from North America| Evolving Opportunities with Astellas Pharma Inc. & Bayer AG | 17000+ Technavio Reports

NEW YORK, June 1, 2022 /PRNewswire/ -- The "Interstitial Cystitis Drugs Market by Type (Oral therapy and Intravesical therapy) and…

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc.…

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ --…

Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting

Astellas investigational nonhormonal treatment meets all primary endpoints, significantly reducing the frequency and severity of vasomotor symptoms associated with menopause…

Astellas Pharma FY21 Core Profit Decreases; Revenue Up 3.7%

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) reported that its fiscal 2021 core operating profit decreased by 2.6% year-on-year…

University Of Tokyo, Astellas Pharma Enter Second Phase Of Collaboration

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the company and the University of Tokyo have entered the second…

University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions

TOKYO, April 25, 2022 /PRNewswire/ -- The University of Tokyo (President: Teruo Fujii, Ph.D.) and Astellas Pharma Inc. (TSE: 4503,…

USD 30.23 billion growth expected in Non-Small Cell Lung Cancer Drugs Market | Evolving Opportunities with AbbVie Inc. and Amgen Inc. | Technavio

NEW YORK, April 20, 2022 /PRNewswire/ -- The global non-small cell lung cancer drugs market size is expected to increase…

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer

- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and…

Globale Pharmaunternehmen unterstützen Turn Biotechnologies bei der Weiterentwicklung seines Zellverjüngungsprogramms

Turn Biotechnologies, Inc.: Mountain View, Kalifornien (ots/PRNewswire) - Daewoong Pharmaceutical und HanAll Biopharma beteiligen sich gemeinsam mit Astellas Venture Management…

CYTOO-Partner Astellas Gene Therapies hat die Ergebnisse einer AGT/CYTOO-Kooperation zur Auswahl klinischer Kandidaten für die Behandlung von DMD auf dem zweiten Gentherapie-Gipfel für Muskelkrankheiten vorgestellt

GRENOBLE, Frankreich--(BUSINESS WIRE)--CYTOO und Astellas Gene Therapies (AGT) sind im Jahr 2020 eine Forschungskooperation eingegangen, um den klinischen AAV-Gentherapie-Kandidaten von…

Astellas hot flashes treatment fezolinetant fails in late-stage study in Asia

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas: Phase 3 Study Of Fezolinetant On VMS Associated With Menopause Did Not Show Efficacy

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that 12-week data from phase 3 MOONLIGHT 1 study of fezolinetant…

Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia

Astellas MOONLIGHT 1TM clinical trial evaluating investigational fezolinetant 30 mg administered once daily TOKYO, March 14, 2022 /PRNewswire/ -- Astellas…

Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports

NEW YORK, March 14, 2022 /PRNewswire/ -- The central nervous system (CNS) stimulant drugs market is fragmented and the vendors…

Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology Target

NEW YORK, March 10, 2022 /PRNewswire/ -- Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to…

Astellas Worth A Look On Revenue Re-Acceleration Potential

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause

TOKYO, March 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

TOKYO and BOTHELL, Wash., Feb. 14, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas")…